苑东生物
(688513)
| 流通市值：88.27亿 | | | 总市值：88.27亿 |
| 流通股本：1.77亿 | | | 总股本：1.77亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 658,897,905.28 | 326,262,896.49 | 1,331,390,248.33 | 1,019,133,615.33 |
| 营业收入 | 658,897,905.28 | 326,262,896.49 | 1,331,390,248.33 | 1,019,133,615.33 |
| 二、营业总成本 | 569,884,268.06 | 295,762,658.95 | 1,122,067,149.82 | 830,690,066.9 |
| 营业成本 | 155,749,378.02 | 73,620,102.51 | 329,515,498.72 | 247,736,615.83 |
| 税金及附加 | 11,695,609.27 | 5,714,581.76 | 19,780,406.98 | 15,422,976.39 |
| 销售费用 | 202,527,618.56 | 118,836,040.38 | 416,232,092.44 | 320,484,840.52 |
| 管理费用 | 48,474,101.74 | 25,027,588.71 | 101,543,357.52 | 68,492,411.71 |
| 研发费用 | 151,010,108.93 | 72,663,064.65 | 265,057,734 | 183,301,396.13 |
| 财务费用 | 427,451.54 | -98,719.06 | -10,061,939.84 | -4,748,173.68 |
| 其中:利息费用 | 1,266,216.25 | 575,929.87 | 2,513,008.66 | 1,890,937.16 |
| 其中:利息收入 | 2,111,313.79 | 1,193,736.59 | 13,104,573.81 | 6,966,483.68 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 10,768,453.67 | 5,866,859.44 | 17,128,662.34 | 13,338,891.52 |
| 加:投资收益 | 2,306,057.61 | 758,947.65 | 39,005,713.4 | 2,496,953.1 |
| 资产处置收益 | 18,530.1 | 19,683.58 | 29,348.33 | 24,531.82 |
| 资产减值损失(新) | -452,665.06 | -4,745.55 | -4,372,647.11 | -3,786,009.34 |
| 信用减值损失(新) | 703,466.73 | 51,341.01 | 216,647.39 | -1,940,618.28 |
| 其他收益 | 30,451,019.46 | 10,169,623.05 | 53,299,424.65 | 43,178,294.68 |
| 四、营业利润 | 132,808,499.73 | 47,361,946.72 | 314,630,247.51 | 241,755,591.93 |
| 加:营业外收入 | 1,805,541.38 | 125,685.99 | 2,640,543.06 | 433,650.02 |
| 减:营业外支出 | 373,947.98 | 86,369.78 | 17,619,761.47 | 99,433 |
| 五、利润总额 | 134,240,093.13 | 47,401,262.93 | 299,651,029.1 | 242,089,808.95 |
| 减:所得税费用 | 22,136,490.76 | 4,119,496.61 | 26,077,160.67 | 21,927,326.29 |
| 六、净利润 | 112,103,602.37 | 43,281,766.32 | 273,573,868.43 | 220,162,482.66 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 112,103,602.37 | 43,281,766.32 | 273,573,868.43 | 220,162,482.66 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 129,751,906.83 | 50,831,021.88 | 284,059,384.18 | 220,162,482.66 |
| 少数股东损益 | -17,648,304.46 | -7,549,255.56 | -10,485,515.75 | - |
| 扣除非经常损益后的净利润 | 93,691,231.05 | 38,192,305.09 | 207,998,682.19 | 172,996,071.09 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.74 | 0.29 | 1.63 | 1.25 |
| (二)稀释每股收益 | 0.74 | 0.29 | 1.63 | 1.25 |
| 九、综合收益总额 | 112,103,602.37 | 43,281,766.32 | 273,573,868.43 | 220,162,482.66 |
| 归属于母公司股东的综合收益总额 | 129,751,906.83 | 50,831,021.88 | 284,059,384.18 | 220,162,482.66 |
| 归属于少数股东的综合收益总额 | -17,648,304.46 | -7,549,255.56 | -10,485,515.75 | - |
| 公告日期 | 2026-08-21 | 2026-04-22 | 2026-04-22 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |